Drugmakers Hold Back Swiss Reimbursement Applications Amid Pricing Concerns
Pharmaceutical companies are increasingly delaying applications for health-insurance reimbursement for new medicines in Switzerland, raising concerns about patient access to innovative treatments. A survey by Swiss pharmaceutical industry association Interpharma found that seven of 22 innovative medicines introduced between January 2025 and June 2026 were not submitted for inclusion on Switzerland’s mandatory health-insurance reimbursement list. […]
Continue Reading